/ Side by side
Exenatide vs Liraglutide
A neutral, side-by-side look at Exenatide and Liraglutide: what each one is, its class, half-life, storage, and the public sources behind it. Educational reference only, not medical advice, dosing, or a recommendation to use either compound.
Exenatide
Byetta · Bydureon
Full profile →Liraglutide
Saxenda · Victoza
Full profile →| Attribute | Exenatide | Liraglutide |
|---|---|---|
| Category | GLP-1 / Metabolic | GLP-1 / Metabolic |
| Half-life | ~2.4 h | ~13 h, subcutaneous |
| Common vial | Varies | Varies |
| Reference | Verified | Verified |
What is Exenatide?
The first GLP-1 receptor agonist brought to market, a synthetic version of exendin-4. Its short terminal half-life is why the original formulation is twice-daily, in contrast to the weekly agonists that followed.
Sources
- FDA label: Byetta (NDA 021773)
What is Liraglutide?
A GLP-1 receptor agonist with a fatty-acid chain enabling self-association and albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-daily administration.
Sources
- FDA labels: Victoza (2010), Saxenda (2014)
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.